Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darusentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB known ✓ | P24530 | 20/20 | 0.78 |
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.61 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darusentan SCHEMBL1068546 | 0.88 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Darusentan SCHEMBL795084 | 0.88 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL13066899 | 0.81 | EDNRB (0.86) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL7934042 | 0.81 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL8021756 | 0.81 | EDNRB (0.86) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL7071036 | 0.79 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL1068402 | 0.78 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2350734 | 0.78 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Darusentan SCHEMBL6895168 | 0.77 | EDNRB (0.80) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Ambrisentan SCHEMBL20769813 | 0.76 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262006-A1 | Selective endothelin type-a antagonists | CONCERT PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262006-A1 | Selective endothelin type-a antagonists | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885NR1I2 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.